ACCUSTEM SCIENCES, INC.
Income Statement
| Line Item | Jun 2024 | May 2024 | Mar 2024 | Mar 2024 | Dec 2023 | Nov 2023 | Sep 2023 | Aug 2023 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $41.7K | — | $23.2K | — | — | — | $20.0K | — |
| SG&A Expense | $236.5K | — | $503.4K | — | — | — | $578.6K | — |
| Operating Income | $-278.2K | — | $-526.6K | — | — | — | $-598.5K | — |
| Operating Margin | — | — | — | — | — | — | — | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-278.2K | — | $-526.6K | — | — | — | $-598.5K | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | $-278.2K | — | $-526.6K | — | — | — | $-598.5K | — |
| Net Margin | — | — | — | — | — | — | — | — |
| EPS (Basic) | $-0.02 | — | $-0.05 | — | — | — | $-0.05 | — |
| EPS (Diluted) | $-0.02 | — | $-0.05 | — | — | — | $-0.05 | — |
| Shares Outstanding (Basic) | 11.3M | 11.3M | 11.3M | 11.3M | 11.3M | 11.3M | 11.3M | 11.3M |
| Shares Outstanding (Diluted) | 11.3M | 11.3M | 11.3M | 11.3M | 11.3M | 11.3M | 11.3M | 11.3M |
| Dividends Per Share | — | — | — | — | — | — | — | — |